Octavio Espinoza - 14 Feb 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Issuer symbol
LGND
Transactions as of
14 Feb 2025
Net transactions value
-$1,150,440
Form type
4
Filing time
19 Feb 2025, 20:38:58 UTC
Previous filing
26 Dec 2024
Next filing
06 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +5,429 +26% $0.000000 26,076 14 Feb 2025 Direct F1
transaction LGND Common Stock Tax liability $330,840 -2,757 -11% $120.00 23,319 14 Feb 2025 Direct F2
transaction LGND Common Stock Award $0 +7,390 +32% $0.000000 30,709 14 Feb 2025 Direct F1
transaction LGND Common Stock Tax liability $456,360 -3,803 -12% $120.00 26,906 14 Feb 2025 Direct F2
transaction LGND Common Stock Tax liability $122,880 -1,024 -3.8% $120.00 25,882 15 Feb 2025 Direct F3
transaction LGND Common Stock Tax liability $93,840 -782 -3% $120.00 25,100 15 Feb 2025 Direct F3
transaction LGND Common Stock Tax liability $146,520 -1,221 -4.9% $120.00 23,879 15 Feb 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs).
F2 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units.
F3 Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.